Methods and compositions are disclosed herein to define a suite of shear-thinning hydrogels exhibiting piezoelectric properties. The piezoelectric materials described can be injected percutaneously or via transcatheter vascular route into a target environment for the locoregional stimulation of cells or tissues using wireless impulses as actuation mechanisms. These external stimuli introduce either an electrical or mechanical response in the implanted piezoelectric materials for medical interventions including tumor ablation, drug delivery, electroporation, chemo-electroporation, neural stimulation, wound healing, cardiovascular applications and musculoskeletal pain management.

An improved osteogenic composition is provided. The composition comprises a foam that contains polymer beads having one or more growth factors such as bone morphogenic protein. Through use of this composition, bone, collagen and/or other tissue growth may be facilitated.

A preparation composition that is easy to produce and enables a preparation with high hardness to be easily obtained, a preparation comprising the composition, and a method for producing the preparation composition are provided. The preparation composition comprises particles containing an active ingredient and a binder. The particles contain the active ingredient in an amount of 80 mass % or more based on the total mass of the active ingredient and the binder, and the coverage of the binder at the surface of the particles is 20% or more. The method for producing the preparation composition includes step 1 of kneading and granulating a mixture containing an active ingredient and a binder in barrels by a twin-screw extrusion method, the temperature in each barrel being 130 C. or less, the binder having a mass average molecular weight of 1,000,000 g/mol or less, and the mixture containing the active ingredient in an amount of 80 mass % or more based on the total mass of the active ingredient and the binder.

The present disclosure is directed to compositions and methods for making a pharmaceutical composition by thermokinetic compounding, wherein the compositions include one or more thermolabile components, for example one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients. The methods comprise thermokinetic processing of the thermolabile components into a composite by blending certain thermolabile components in a thermokinetic mixer using multiple speeds during a single, rotationally continuous operation. The composite can be further processed into pharmaceutical compositions by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.

A process for preparing a powder for reconstitution as a suspension includes the following steps: First, complexing Valaciclovir with an ion exchange resin and forming Drug-Resin complex (DRC) particles. The complexing includes Dry blending of Drug:Ion Exchange Resin in a ratio 1:0.8 to form a blend; Kneading the blend with water in a ratio of Drug:Ion Exchange Resin:Water 1:0.8:0.5 to form a wet mass; Drying of the wet mass at 40 C.
Next, milling of the Drug-Resin complex particles until particle size gets less than 250 m, and then dry mixing of the Drug-Resin complex particles with excipients to form an internal phase. The excipients of the internal phase comprise a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. Next, mixing the internal phase with excipients of an external phase to form the powder, and then sifting the powder to eliminate any clumps.

Compositions of particles having at least 95% by weight of cisplatin and a specific surface area (SSA) of at least 3.5 m.sup.2/g. methods for their use. and methods for their production are provided.

A system for producing a microsphere includes a first raw material storing to store a first raw material is stored, a second raw material storing part to store a second raw material including a solvent, a biodegradable polymer, and a drug, an emulsion generating part to continuously form an emulsion including the first raw material of a continuous phase and the second raw material of a dispersed phase, a first solvent extracting and removing part to accommodate the emulsion formed from the emulsion generating part, and extract and remove the solvent from the dispersed phase of the emulsion to form a microsphere, and a second solvent extracting and removing part spaced apart from the first solvent extracting and removing part, to accommodate the emulsion formed from the emulsion generating part, and extract and remove the solvent from the dispersed phase of the emulsion to form a microsphere.

Disclosed herein, in part, are pharmaceutical formulations for oral mucosal (e.g., sublingual and/or buccal) administration comprising micronized aspirin, (e.g., 91 mg to 200 mg micronized aspirin), a buffer, a surfactant, and one or more pharmaceutically acceptable excipients, wherein the pH of a solution of the formulation dissolved in 1 mL distilled water is less than or equal to 3. Methods of treating a subject in need thereof comprising administering one or more disclosed pharmaceutical formulations to the subject are also provided herein.